

# Neutropenia due to palbociclib: A word of caution?

Sir,

Palbociclib is an oral, selective, reversible inhibitor of cyclin-dependent kinase 4 and 6, which prevents cell cycle progression from G1 to S phase.<sup>[1]</sup> It was found to be beneficial in hormone-resistant advanced breast cancer when added to letrozole versus letrozole with placebo. Following this study (PALOMA-1), palbociclib got an accelerated approval, a way to rapidly review the clinical data (instead of a series of scheduled meetings) and faster marketing of drugs for such life-threatening diseases. In a subsequent phase 3 study (PALOMA-3), addition of palbociclib to fulvestrant in patients suffering from hormone-sensitive advanced breast cancer has also shown a survival benefit.<sup>[2]</sup>

Palbociclib has shown to cause a fair amount of severe neutropenia, resulting in significant interruptions and modifications of palbociclib [Table 1]. Neutropenia was associated with a very low incidence of febrile neutropenia in both these trials [Table 1] where patients in good general condition were carefully selected and monitored intensively. In actual clinical practice in the real world, the risk of infections during neutropenia due to palbociclib may increase and would warrant caution. Clinicians will certainly be afraid to prescribe it to endocrine-resistant, multiply relapsed, metastatic breast cancer patient with an Eastern Cooperative Oncology Group performance status 2–3, the scene where exactly the current unmet need lies.

**Table 1: Neutropenia with palbociclib**

	PALOMA 1 study <sup>[3]</sup> (%)	Present (PALOMA 3) study <sup>[2]</sup> (%)
<i>n</i> , phase	165, Phase II	521, Phase III
Arms	Palbociclib + letrozole (vs. letrozole)	Palbociclib + fulvestrant (vs. fulvestrant)
Incidence of URTI	31 (vs. 1)	19.4 (vs. 16)
Incidence of Grade 3/4 neutropenia	54 (vs. 1)	62 (vs. 0.6)
Discontinuation due to adverse events	7 (vs. 2)	2.6 (vs. 1.7)
Mean relative dose intensity of palbociclib	94	91.7
Prior use of (neo) adjuvant chemotherapy	40 (vs. 46)	41.5 (vs. 43.1)
Chemotherapy used for metastases	0	30.8 (vs. 36.2)
Dose interruption in palbociclib arm	33	NA
Dose modification in palbociclib arm	40	31.6
Cycle delays in palbociclib arm	45	NA
Dose reductions in palbociclib arm	40	31.6

URTI – Upper respiratory tract infections; NA – Not available

Whether this neutropenia is a class effect of this drug or due to dose and schedule effect is not known.

The recommended dose of palbociclib (125 mg/day orally for 3 weeks, followed by 1 week off) is derived from a very few phase, 1/2 studies resulting in limited information about tolerability.<sup>[3,4]</sup> Hence, to confirm its relationship with neutropenia, pharmacokinetic studies are needed in future and that should revisit the dosage and schedule of palbociclib.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

*Raja Pramanik, Ranjit Kumar Sahoo, Ajay Gogia*

Department of Medical Oncology, BRA-IRCH, All India Institute of Medical Sciences, New Delhi, India.  
E-mail: drrajapramanik@gmail.com

## REFERENCES

- Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, *et al.* Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Mol Cancer Ther* 2004;3:1427-38.
- Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2015;373:1672-3.
- Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, *et al.* The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. *Lancet Oncol* 2015;16:25-35.
- Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, *et al.* Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. *Clin Cancer Res* 2012;18:568-76.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

## Access this article online

### Quick Response Code:



Website:  
www.ijmpo.org

DOI:  
10.4103/0971-5851.190351

**How to cite this article:** Pramanik R, Sahoo RK, Gogia A. Neutropenia due to palbociclib: A word of caution?. *Indian J Med Paediatr Oncol* 2016;37:206.